Galera claims positive update in pancreatic cancer but doesn’t report p-values; Amgen launches Canadian fund in tandem with CCRM

Malvern, PA-based Galera Therapeutics released updated follow-up data Wednesday afternoon for a Phase I/II trial in pancreatic cancer, though it did not reveal any p-values associated with the results.

According to the company, after six months of follow-up from 42 patients with locally advanced pancreatic cancer,...

Click to view original post